CirCode Biomed, a China‑based startup developing circular RNA therapeutics, received FDA clearance to begin a US clinical trial for its circular RNA candidate. The IND greenlight marks one of the first U.S. clinical efforts for circular RNA, an emerging modality that uses covalently closed RNA to enhance stability and protein expression compared with linear mRNA. CirCode’s clearance enables early‑phase testing of safety and pharmacology in humans and signals broader investor and regulator interest in novel RNA platforms beyond conventional linear mRNA therapeutics.